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Intravenous calcitriol normalizes insulin sensitivity in uremic patients.
Recent studies suggest that secondaiy hyperparathyroidism and/or vitamin
D deficiency are responsible for the insulin resistance in chronic renal
failure. We investigated the effect of a 12-week intravenous treatment with
1,25 dihydroxycholecalciferol on glucose metabolism in 10 hemodialysis
patients compared with 10 healthy control subjects by the frequently-
sampled intravenous glucose tolerance test, analyzed with the minimal
model technique. Compared to control subjects, the uremic patients
featured elevated levels of parathyroid hormone (432 60 vs. 41 4
ng/liter, P < 0.001), insulin resistance (insulin sensitivity index, S1: 4.9
0.8 vs. 9.5 0.9 min1/(jiU/ml), P < 0.002), increased posthepatic insulin
delivery (6.48 2.48 vs. 2.73 3.14 nmol/liter in 4 hr, P < 0.001) and a
reduced C-peptide fractional clearance (0.033 0.004 vs. 0.085 0.009
min', P < 0.0002). Following treatment with 1,25 dihydroxycholecalcif-
erol, the parathyroid hormone levels decreased significantly to 237 30
ng/liter (P < 0.05), the insulin sensitivity index (S1: 9.6 2.2, P < 0.05)
reached a value similar to that of control subjects, and posthepatic insulin
delivery decreased to 4.63 0.83 nmol/liter in 4 hr (P < 0.01),while all the
other parameters remained unchanged. In summary, uremic patients with
secondary hyperparathyroidism were found to be severely insulin resistant
and hyperinsulinemic. Intravenous vitamin D treatment led to a significant
reduction of parathyroid hormone levels and to a complete nonnalization
of insulin sensitivity in the hemodialysis patients. Thus, intravenous 1,25
dihydroxycholecalciferol improves insulin resistance in uremic patients,
acting per se or by reducing secondary hyperparathyroidisni.
Impaired insulin secretion and insulin resistance are character-
istic features of patients with chronic renal failure [1—4]. The
pathogenesis of glucose intolerance in uremia, however, is still
unknown. In animal models [5, 6] as well as in studies in humans
[7, 8], it has been shown that secondary hyperparathyroidism due
to chronic renal failure can inhibit insulin release from the
pancreatic beta cells. Correction of hyperparathyroidism by para-
thyroidectomy is associated with improvement of insulin secre-
tion, but does not affect insulin resistance [7, 8]. Nevertheless,
parathyroidectomy can lead to normal glucose tolerance, if in-
creased insulin secretion overcomes the reduced tissue insulin
sensitivity in the uremic patients. Recent evidence suggests that
vitamin D deficiency might play a major role in the pathogenesis
of impaired glucose metabolism in uremia [7]. However, it is still
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controversial, if repletion of vitamin D deficiency by itself can
really improve insulin release [6, 7]. Mak [9] reported that acute
intravenous 1,25 dihydroxycholecalciferol (1,25DCC) administra-
tion to vitamin-D-withdrawn hemodialysis patients increased in-
sulin secretion and corrected glucose tolerance independent of
the unchanged levels of intact parathyroid hormone, calcium or
phosphorus. In a different study using the hyperglycemic clamp
technique the author also reports a significant increase in insulin
sensitivity after one single dose of intravenous vitamin D [10].
However, until now, it is not known if intravenous administration
of 1,25DCC for a longer period of time can effectively influence
insulin sensitivity and/or insulin secretion. In contrast to oral
administration of 1,25 DCC, intravenous treament effectively
reduces parathyroid hormone levels in hemodialysis patients by
achieving significantly higher 1,25 DCC plasma levels [11—13]. The
aim of this study was to obtain a wide metabolic portrait (insulin
sensitivity, glucose effectiveness, beta cell insulin release and
hepatic extraction of insulin) of hemodialysis patients before and
after 12 weeks of intravenous administration of 1,25 dihydroxy-
cholecalciferol, assessed by the frequently sampled intravenous
glucose tolerance test analysed with the minimal model technique.
Methods
Subjects
We investigated 10 hemodialysis patients in comparison to 10
sex, age and body weight matched control subjects. The clinical
characteristics of all subjects are shown in Table 1. The patients
were on regular hemodialysis three times per week for on average
45 months (range, 12 to 144 months). The standard dialysate was
containing 1.5 mmol/liter calcium. Dietary calcium intake and the
supplementation with phosphate binders (mostly aluminum con-
taining) remained unchanged throughout the study. All patients
showed severe secondary hyperparathyroidism with about 10-fold
elevated serum levels of parathyroid hormone for at least 12
months (458.7 65 ng/liter, six months before study). Five
patients were receiving oral 1,25 dihydroxycholecalciferol before
the investigation. These patients discontinued oral vitamin D
supplementation four weeks before study. The patients were
re-investigated after 12 weeks of intravenous administration of
1,25 dihydroxycholecalciferol. Therapy was startd with a dose of
1 .tg 1,25DCC after each hemodialysis (Cacijex Abbot, Chicago,
Illinois, USA). The subsequent doses were adjusted to the plasma
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Table 1. Clinical characteristics of the 10 hemodialysis patients (HD, 5 males and 5 females, age: 40.1 0.4) before and after vitamin D repletion
and of 10 healthy control subjects (CS, 6 males and 4 females, age: 38.0 0.3)
HD before
vitamin D
HD after
vitamin D CS P°
BMI kg/rn2
PTH intact ng/iiter
22.6 0.8
432 60
22.8 0.8
237 30"
23.0 0.9
41 4
NS
<0.001
Magnesium rng/dl 2.1 0.2 1.9 0.1 1.6 0.1 NS
Potassium mmol/liter 5.8 0.4 6.0 0.5 4.2 0.1 <0.01
Calcium mmol/liter 2.18 0.03 2.25 0.03 2.35 0.04 <0.01
Phosphorus mmol/liter 1.80 0.19 1.94 0.18 1.06 0.04 <0.01
Creatinine mg/dl 11.5 1.1 10.7 0.6 0.90 0.01 <0.0001
Urea nitrogen mg/dl 71.2 5.0 66.7 4.1 15.4 1.8 <0.0001
Basal glucose mmol/liter
Basal insulin pmol/liter
4.3 0.15
90 12
4.4 0.11
71.4 7.2"
4.6 0.11
36 6
NS
<0.0005
Triglycerides mg/dl 197 23 166.8 12.8 163 10.5 NS
Cholesterol rng/dl 193.6 10.4 185.5 11.4 188.4 14.3 NS
BMI is body mass index, and PTH is parathyroid hormone.
a Testing the difference between CS and HD before vitamin Db P < 0.05, comparing HD before vs. after vitamin D treatment
calcium levels. On the average the dose was 0.96 0.08 jig after
hemodialysis (median, 1 jig; Qi, 0.85 jig; Q3, 1 jig). Serum 1,25
dihydroxycholecalciferol was measured before starting intrave-
nous calcitriol and at the end of the study (44 hours after the last
dose). None of the subjects investigated had any family histoiy of
diabetes; no patient was diabetic. All subjects were maintaining
their regular diet, none was taking any drug known to affect
carbohydrate metabolism and liver function. The Ethical Com-
mittee of the Medical Department of the University of Vienna
approved the protocol and informed consent was obtained from
each subject prior to investigations.
Tests
The subjects underwent a frequently sampled intravenous
glucose tolerance test (FSIGT), which started at 8:00 a.m., after
an overnight fast. A catheter was inserted into an antecubital vein
and basal blood samples were drawn at —20, —10 and —1 minutes.
At time zero glucose (300 mg/kg) was injected in 30 seconds.
Additional samples were obtained from a contralateral antecubi-
tal vein at time 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 25, 30, 40, 50,
60, 70, 80, 90, 100, 110, 120, 140, 160, 180, 210 and 240 minutes via
a three-way stopcock connected with the catheter. Blood was
rapidly centrifuged and glucose immediately measured by oxidase
method (Beckman Analyzer). The measurement error was
The remaining plasma was stored at —20°C for subse-
quent insulin and C-peptide determination. Insulin (Pharmacia,
Uppsala, Sweden) and C-peptide (Byk Mallinckrodt), as well as
serum levels of intact parathyroid hormone (Nichols Institute
Diagnostics, San Juan Capistrano, California, USA) were mea-
sured by commercially available radioimmunoassays. The interas-
say coefficient of variation was approximately 10% for the insulin
and the C-peptide assay.
FSIGT data analysis
FSIGT data were submitted to the computer programs which
calculate the characteristic metabolic parameters by fitting glu-
cose, insulin and C-peptide data to the minimal models which
describe the time courses of glucose, insulin, and C-peptide
concentration. The models, originally developed in dogs [14, 151
have found a wide application in human studies [reviewed in 16,
17]. The minimal models have previously been described in detail
[18, 19] and here we briefly present what is useful to the
understanding of their application in this study. The glucose
disappearance model [14, 18, 20—22] accounts for the effect of
insulin and glucose on glucose disappearance following the exog-
enous glucose injection. It provides parameter 5, (min1/(jiU/
ml)), the insulin sensitivity index, defined as the ability of insulin
to enhance glucose disappearance and to inhibit hepatic glucose
production; and parameter SG (min1), the glucose effectiveness,
defined as the ability of glucose per se to enhance its own
disappearance and to inhibit glucose production independent of
any dynamic change of insulin. The two-compartment C-peptide
minimal model [19, 23] accounts for the effect of glucose on the
changes of C-peptide concentration during an FSIGT by quanti-
fying the ability of the beta-cells to secrete the peptide in response
to the glycemic stimulus and C-peptide kinetics after its entry into
the peripheral circulation. The model provides parameter kc,,
(min1), which is the C-peptide fractional clearance rate, that is,
the peptide disappearance in unit time per unit volume, the
C-peptide secretion per unit volume CPS(t), the sensitivity to the
glucose stimulation of the first (t1, min' pM/(mg/dl)) and second
min2pM/(mg/dl)) phase of the dynamic (prehepatic, supra-
basal) insulin release. Basal insulin and C-peptide secretion rate,
per unit volume, BSR (pM/mm), may be computed by multiplying
the clearance rate k01 by the basal C-peptide concentration. The
minimal model of insulin FSIGT data [15], by analyzing periph-
eral hormone concentration provides quantitative figures of
posthepatic insulin delivery per unit volume, that is, IDR(t), the
time course of insulin appearance into the systemic circulation,
(BDR) (pM/mm), the basal delivery rate, and the total amount of
hormone reaching the peripheral circulation.
Calculations
The estimation of the parameters of the models was carried out
using a non-linear least squares estimation technique by the
computer program MINMOD [20], which was modified to ac-
count also for C-peptide data [23]. A constant variance structure
was assumed for the measurement error. Accuracy and precision
of the estimates were evaluated according to the validation
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criteria of model identification [24]. Because insulin and C-
peptide are secreted in equimolar fashion, CPS(t) also represents
the beta-cell insulin release. The total amount of prehepatically
secreted (TIS, iO M in 4 hr) and posthepatically delivered
insulin (TID, io M in 4 hr) were computed by the integral,
between zero and 240 minutes, of CPS(t) and IDR(t), respec-
tively. Hepatic insulin extraction, HE(t), as a percent of the
secreted hormone, may be computed as the difference between
CPS(t) and IDR(t), normalized to CPS(t) [19]. The total areas
under the insulin and C-peptide concentration curves were calcu-
lated by using the trapezoidal integration. Initial glucose distribu-
tion volume VD (liter) was computed as the ratio between the
administered glucose dose and the extrapolated concentration at
time zero.
Statistical analysis
Differences in mean values between the haemodialysis patients
with vitamin D deficiency and the control subjects were tested for
significance by means of the analysis of variance. The significance
of the differences between the patients before and after vitamin D
repletion were calculated by paired Student's t-test. All data and
results are given as means SE unless otherwise designated.
Converting factors are: glucose 1 mgldl = 0.056 mmol/liter; insulin 1
piJ/ml = 6 pmollliter; C-peptide 1 nglml = 0.331 nmol/liter.
Results
FSIGT
The time course of the average glucose, insulin and C-peptide
concentrations are shown in Figure 1. Basal glucose and insulin
levels are reported in Table 1. Despite similar basal and stimu-
lated glucose levels in the hemodialysis patients (HD) and in the
control subjects (CS), HD featured more than doubled basal and
stimulated (peak: 888 102 vs. 390 30 pmol/liter, P < 0.0006)
insulin concentrations. The basal (3.84 0.50 vs. 0.51 0.06
nmol/liter, P < 0.0005; HD vs. CS) as well as the supra-basal
C-peptide concentrations (peak 6.59 0.69 vs. 2.63 0.19
nmol/liter, P < 0.0005) were also markedly elevated in the uremic
patients compared to the control subjects. The total area under
the curve of insulin resulted 35.4 3.6 nmol/liter in 240 minutes
in the hemodialysis patients compared to 12 0.6 (P < 0.01) in
the control subjects and that of C-peptide was also markedly
elevated in the uremic patients compared to the control subjects
(1.32 0.13 vs. 0.215 0.049 iimol/liter in 240 mm; P < 0.0001;
HD vs. CS). In addition, the C-peptide value of the last sample at
240 minutes (4.72 0.49 nmol/liter) remained elevated in the
patients and different from the pre-injection level (P < 0.005).
Model parameters
The metabolic parameters obtained by the model analysis are
shown in Table 2. The tissue insulin sensitivity index, S1, was
markedly decreased in HD, while the glucose effectiveness, 5G'
was not different in both groups. Initial glucose distribution space
was slightly, although insignificantly, elevated in the patients. The
C-peptide fractional clearance rate (k01) was decreased in HD, as
expected in patients with overt renal failure. The basal prehepatic
insulin secretion rate (BSR) and total insulin secretion (TIS =
46.3 7.5 vs. 22.5 3.4 nmol/liter in 240 mm, < 0.01, HD vs.
C, respectively) were significantly elevated in HD. Sensitivities of
the first and second phase responsiveness, the parameters t and
0 60 120 180 240
0 60 120 180 240
(1)2, were 465.8 61.7 min' pM/(mg/dl)) and 0.091 0.02 min2
pM/(mg/dl) in HD compared to 137.9 21.8 and 0.083 0.017 in
the control subjects (1), P < 0.0005, HD vs. C). Basal (BDR) as
well as total (TID) posthepatic insulin delivery were also found to
be significantly higher in the hemodialysis patients than in control
subjects. Mean hepatic insulin extraction was not significantly
different between both groups (86 2.5 vs. 84 3%, HD vs. C).
Effect of the repletion of vitamin D in hemodialysis patients
Twelve weeks after intravenous administration of 1,25 dihy-
droxycholecalciferol the plasma levels of parathyroid hormone
decreased significantly (Table 1), whereas calcium and phospho-
rus levels remained unchanged. Serum 1,25 dihydroxycholecalcif-
erol levels increased from 17.1 7.1 to 39.5 7.3 pglml (P <
0.01). The lipid metabolism was not altered by intravenous
vitamin D treatment (Table 1).
The insulin sensitivity parameter increased significantly and
reached the level similar to that of the healthy control subjects
(Table 2), whereas glucose effectiveness was not affected by
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Fig. 1. Average FSIGT time course of glucose, insulin and C-peptide
concentrations in control subjects (open circles) and in patients before
vitamin D treatment (closed circles). Glucose (0.33 g/kg) was injected at
time zero.
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Table 2. Model estimated and calculated parameters from the FSIGT
for 10 controls (CS) and 10 patients on hemodialysis (HD) before and
after vitamin D repletion
CS
HD before
vitamin D
HD after
vitamin D P
Glucose
S1 9.34 0.97 4.95 0.76 9.95 2.10k' <0.002
S0 0.031 0.005 0.025 0.006 0.021 0.004 NS
V0 16.8 0.8 18.5 1.0 18.3 1.1 NS
Insulin delivery
BDR 6.3 1.0 14.1 2.5 12.0 1.9 <0.001
TID 2.7 3.1 6.7 1.08 4.6 0•8b <0.001
C-peptide kinetics
km 0.085 0.009 0.033 0.004 0.031 0.002 <0.0002
BSR 42 8 145 36 137 18 <0.006
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Parameter meanings and units are: S1 (insulin sensitivity) i0 min/
(UIml); S0 (glucose effectiveness) min1; VD (volume of distribution of
glucose) percent of body weight; BDR (basal posthepatic insulin delivery
rate) pM/mm; TID (total posthepatic insulin delivery) flM in 4 hrs; km(C-peptide fractional clearance rate) min'; BSR (basal insulin secretion
rate) pM/mm.aTesting the difference between the hemodialysis patients (HD) before
vitamin D repletion and the control subjects (CS)
b P < 0.02 testing the difference between the hemodialysis patients
before and after vitamin D repletion
vitamin D treatment. FSIGT patterns before and after 1,25
dihydroxycholecalciferol administration are shown in Figure 2.
The basal and stimulated glucose concentrations did not really
change after treatment. C-peptide concentrations were also not
statistically different from those before treatment (area under the
curve: 1.63 0.14 jimollliter in 240 mm). However, the basal
(71.4 7.2 pmol/liter, P < 0.01) and stimulated (peak 636 144
pmol/liter, P < 0.005) insulin levels showed a significant decrease
after vitamin D administration. The total area under the curve for
insulin was also lower (27.6 3 nmol/liter in 240 mm, P < 0.02),
reflecting a lower post-hepatic insulin delivery (TID). The time
course of the hepatic insulin extraction during the FSIGT before
and after treatment is shown in Figure 3. Dynamic suprabasal
hepatic insulin extraction increased significantly (86.4 0.4 vs.
90.8 0.5%; P < 0.001, before vs. after vitamin D treatment,
respectively), while all the other model calculated parameters did
not change significantly after vitamin D treatment.
Discussion
It is well established that uremic patients feature abnormalities
in insulin secretion, insulin metabolism and tissue insulin sensi-
tivity [1—4]. Apart from changes in the electrolytes, the secondary
hyperparathyroidism and/or vitamin D deficiency are supposed to
play a major role in the pathogenesis of uremic glucose intoler-
ance and insulin resistance [5—12]. However, the underlying
mechanisms are not yet fully understood and the role of elevated
parathyroid hormone levels on insulin secretion is controversial.
Several studies reported that patients with primary hyperparathy-
roidism are insulin resistant and hyperinsulinemic [5, 25—27].
However, two studies in dogs could not confirm a direct effect of
parathyroid hormone per se on hyperinsulinemia and insulin
resistance [5, 25]. Akmal et al [5], using an uremic parathyroid-
ectomized dog model, reported that elevated PTH levels caused
glucose intolerance due to a reduction in insulin secretion, Fadda
et al [6] studied the effects of chronic renal failure and secondary
hyperparathyroidism on insulin release and reported that acute
Time, minutes
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Fig. 2. Average FSIGT time course of glucose, insulin and C-peptide
concentrations in patients before (closed circles) and after (closed triangles)
vitamin D treatment. Glucose (0.33 g/kg) was injected at time zero. Note
the different C-peptide scale, compared to Fig. 1.
exposure of the beta cells to parathyroid hormone stimulates
glucose-induced insulin secretion modulated by an increase in
cytosolic calcium, whereas chronic exposure to high parathyroid
hormone concentrations led to inhibition of insulin release from
the pancreas [28]. Mak et al [71 studied uremic patients on
hemodialysis with uncontrollable hyperparathyroidism, character-
ized by glucose intolerance and insulin resistance, before and after
surgery, and reported that an increase in insulin secretion could
normalize glucose tolerance despite unchanged insulin-resistance.
In a subsequent study in pre-dialysis uremic children, Mak et al
[29] demonstrated that medical correction of hyperparathyroid-
ism by high dose phosphate binders and vitamin D supplementa-
tion can lead to a significant improvement in glucose metabolism.
Thus, it was suggested that either the high parathyroid hormone
levels or low concentrations of plasma 1,25DCC might inhibit
insulin secretion and cause glucose intolerance in insulin-resistant
uremic patients [30]. These conflicting results concerning the role
of secondary hyperparathyroidism and/or vitamin D deficiency in
uremia stimulated the present study. In particular, no data about
the long term effects of intravenous vitamin D treatment on
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Fig. 3. Time course of the hepatic insulin extraction expressed in percent of
the hormone released 1 the beta-cell after vitamin D treatment (closed
triangles), compared with that of pre-treatment (closed circles).
glucose metabolism are available. We therefore evaluated glucose
and insulin metabolism before and after 12 weeks of intravenous
1,25DCC supplementation in uremic patients with secondary
hyperparathyroidism.
Our results confirmed severe insulin resistance in hemodialysis
patients, the insulin sensitivity index being 47% lower in the
uremic patients compared with controls. In fact several studies
have demonstrated tissue insensitivity to insulin to be the domi-
nant carbohydrate defect in uremia [1, 2, 4]. The glucose effec-
tiveness [22] did not differ between the patients and controls, thus
the glucose disappearance, induced by glucose per se, was appar-
ently not affected by the uremia.
We infer on beta cell activity and hyperinsulinemia before and
after 1,25 dihydroxycholecalciferol treatment, both analyzing the
areas under the curves (qualitative analysis, but model indepen-
dent), and with modeling analysis (quantitative, but under the
assumption that some hypotheses hold). The former shows an
unequivocally marked elevated and sustained insulin and C-
peptide concentration both at basal (pre-injection and at the end
of the test) and in dynamic conditions. Of course, the causes of
this may be either increased secretion or decreased clearance or
both. The modeling analysis demonstrated a reduced C-peptide
clearance, as expected for a compound mostly degraded in the
kidneys. In addition, the C-peptide model indicates that insulin
secretion is significantly increased in uremics compared to normal
subjects. A reason for the augmented insulin secretion may be a
compensatory mechanism to overcome peripheral insulin resis-
tance [31]. Since tissue insensitivity to insulin is uniformly present
among uremic patients, normal glucose tolerance will be main-
tained only if the beta cells can augment their insulin secretion
sufficiently to compensate for the insulin resistance. With this
respect, an increase of B-cell sensitivity to glucose (mostly first
phase) was detected. In fact, our patients showed similar basal and
stimulated glucose concentrations as the healthy control subjects
indicating normal glucose tolerance.
The peripheral insulin concentration was also found to be
markedly higher in the patients than in control subjects. Also the
corresponding model derived parameters, the basal as well as total
posthepatic insulin delivery, were more than doubled in the
patients compared to controls. This finding was reflected in the
observation that hepatic insulin extraction did not differ between
patients and control subjects. Thus, hepatic extraction of insulin
does not seem to be affected by uremia. In fact, insulin is almost
totally degraded by the liver and since our patients had no signs of
impaired liver function, they should be expected to normally
extract insulin, as also confirmed by the modeling analysis.
Mondon, Dolkas and Reaven [32], measuring the extraction of
porcine insulin during recycling perfusion of isolated liver from
nephrectomized rats, have also shown that insulin removal by the
liver was not affected by uremia, and that hepatic insulin extrac-
tion did not differ between normal and uremic rat liver.
After 12 weeks of intravenous treatment with 1,25DCC the
insulin sensitivity index, S, rose to the value of the healthy
controls. The suprabasal, dynamic insulin concentration as well as
the concentration of parathyroid hormone markedly decreased
after intravenous vitamin D supplementation. As there were no
real changes in the electrolytes (calcium, phosphorus, potassium
or magnesium) in the patients before and after the intravenous
1,25DCC, they cannot be involved in the change of insulin
metabolism after vitamin D treatment. Abnormalities in lipid
metabolism are commonly found in patients with chronic renal
failure [33, 34] and hypertriglyceridemia can cause insulin insen-
sitivity. It has recently been reported [35] that oral calcitriol
therapy has been associated with a positive effect on triglyceride
levels in hemodialysis patients. However, the triglyceride and
cholesterol levels in the patients were not significantly elevated
compared to the control subjects and also did not change signif-
icantly after 12 weeks of intravenous calcitriol treatment. Lind et
al [36] also found no alterations in lipid metabolism following
calcitriol treatment in uremic patients. Impaired lipid metabolism
does not seem to play an important role in the insulin resistance
syndrome of chronic uremia [37], and alterations in lipid metab-
olism are not involved in the improvement of insulin sensitivity
after intravenous vitamin D therapy. Thus, intravenous calcitriol
treatment by itself or by a decrease in parathyroid hormone levels
leads to a normalization in glucose and insulin metabolism.
Several studies have shown that intravenous vitamin D supple-
mentation leads to about fourfold higher plasma peak responses
compared to the oral preparation. Intravenous treatment yields a
more efficient suppression of parathormone secretion and allows
a greater delivery to peripheral tissues, which might increase
important biological effects of the vitamin [11—13]. Various animal
studies showed that the endocrine pancreas is a target for
1,25DCC, the active metabolite of vitamin D [38, 39] and that this
metabolite seems to play a major role in the modulation of insulin
secretion [40, 41]. In a vitamin D depleted rat model it has been
shown that dietary vitamin D repletion significantly increased
insulin secretion [40] and vitamin D deficiency was associated with
an inhibition of pancreatic insulin release [41]. Mak [9] reported
that hemodialysis patients regained close-to-normal glucose tol-
erance by becoming hyperinsulinemic after a single intravenous
dose of 1,25DCC at 2 xgIm2 given two hours before the conven-
tional intravenous glucose tolerance test or the clamp study. Since
the patients studied featured normal glucose tolerance and com-
pensatory insulin hypersecretion, a vitamin D induced increase in
insulin secretion would be of little therapeutic benefit. Indeed, we
observed no significant change in insulin secretion and a decrease
in posthepatic insulin delivery after 12 weeks of intravenous
vitamin D treatment. We therefore have to assume a direct effect
of intravenous vitamin D administration on insulin sensitivity. In
this context a recent study of Mak [10] is of considerable interest
120
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investigating the effect of a single dose of intravenous vitamin D
on insulin sensitivity by means of the euglycemic clamp technique
in children with chronic renal insufficiency. He clearly showed an
increase in insulin sensitivity induced by vitamin D combined with
an increase in insulin secretion. Since serum concentrations of
intact parathyroid hormone, calcium, magnesium, potassium, urea
nitrogen and creatinine were not significantly changed in this
study, the authors concluded that vitamin deficiency independent
of parathyroid hormone and calcium levels contributes to the
disturbances in glucose metabolism and insulin secretion.
In accordance to the acute effect of one single dose of intrave-
nous vitamin D, chronic treatment over 12 weeks with intravenous
1,25DCC led to a significant increase in insulin sensitivity in
uremic patients. However, in contrast to the acute effect of
vitamin D we did not find a modulating effect of vitamin D on
insulin secretion. This might be due to the fact that the patients
studied had no defect in insulin secretion and showed compensa-
tory beta cell hypersecretion in response to insulin resistance. In
addition, after chronic intravenous 1,25DCC treatment we ob-
served a significant amelioration of secondary hyperparathyroid-
ism, which might also contribute to the improvement in insulin
sensitivity. However, since an improvement of insulin sensitivity
was already observed after one single dose of intravenous vitamin
D [10], a direct effect of 1,25DCC on insulin sensitivity is more
likely. The mechanism by which vitamin D affects insulin sensitiv-
ity remains unclear. In this context, a recent in vitro study showing
that vitamin D increases insulin receptor mRNA levels is of
considerable interest [42]. Finally, our analysis showed an increase
in hepatic insulin extraction after vitamin D treatment. We do not
have an explanation of this, but we can hypothesize that a sort of
compensatory mechanism occurs which tries to avoid excessive
hyperinsulinemia in a situation of relatively normal insulin sensi-
tivity. However, further studies, ad hoc performed, are necessary
to clarify the effect of calcitriol on the liver action on insulin
degradation.
In summary, the patients with renal insufficiency featured
insulin resistance, which was normalized after vitamin D reple-
tion, and secondary hyperparathyroidism, which was significantly
reduced after treatment. We cannot differentiate if the secondary
hyperparathyroidism or vitamin D deficiency were responsible for
the low insulin sensitivity. Nevertheless, we can conclude that
intravenous 1,25DCC treatment by itself or by reduction of
secondary hyperparathyroidism could be useful to improve or
even reverse insulin resistance commonly found in uremic pa-
tients.
Reprint requests to Prof Dr. R. Prager, Department of Endocrinology and
Metabolism, Medical Clinic III, University of Vienna, Wahringer Gurtel
18-20, 1090 Wien, Austria.
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